Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ)

• Company Description    Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 141

• Price / Volume Information    Yesterday's Closing Price: $3.80 Daily Weekly Monthly 20 Day Moving Average: 560,795 shares Shares Outstanding: 60.42 (millions) Market Capitalization: $229.60 (millions) Beta: 1.26 52 Week High: $5.55 52 Week Low: $2.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.94% -10.54% 12 Week -10.17% -16.95% Year To Date -3.31% -13.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 HAYDEN AVENUE - LEXINGTON,MA 02421 USA ph: 857-259-5340 fax: - investors@voyagertherapeutics.com http://www.voyagertherapeutics.com

• General Corporate Information    Officers Alfred Sandrock - Chief Executive Officer; President; and Director Michael Higgins - Chairman Nathan Jorgensen - Chief Financial Officer Grace E. Colon - Director James Geraghty - Director Peer Information Voyager Therapeutics, Inc. (CORR.) Voyager Therapeutics, Inc. (RSPI) Voyager Therapeutics, Inc. (CGXP) Voyager Therapeutics, Inc. (BGEN) Voyager Therapeutics, Inc. (GTBP) Voyager Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92915B106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 60.42 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $229.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.54 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: - Price / Sales: 6.29 EPS Growth vs. Year Ago Period: 11.32% vs. Previous Quarter: -2.17% Sales Growth vs. Year Ago Period: -59.94% vs. Previous Quarter: -83.09% ROE 03/31/26 - -55.97 12/31/25 - -51.35 09/30/25 - -48.94 ROA 03/31/26 - -43.12 12/31/25 - -39.38 09/30/25 - -37.38 Current Ratio 03/31/26 - 8.42 12/31/25 - 7.64 09/30/25 - 6.19 Quick Ratio 03/31/26 - 8.42 12/31/25 - 7.64 09/30/25 - 6.19 Operating Margin 03/31/26 - -319.61 12/31/25 - -296.53 09/30/25 - -404.85 Net Margin 03/31/26 - -319.61 12/31/25 - -296.53 09/30/25 - -404.85 Pre-Tax Margin 03/31/26 - -319.27 12/31/25 - -296.17 09/30/25 - -402.55 Book Value 03/31/26 - 2.87 12/31/25 - 3.53 09/30/25 - 3.96 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©